PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

Helsinki, Finland - More than 16 years after the first patient was enrolled in the Scandinavian Simvastatin Survival Study (4S), the study drug has been shown unequivocally to improve survival over ...

About 40% of patients with diagnosed heart failure did not pursue future cardiology consultations, regardless of the initial severity of their condition. A single ...

Biofrontera announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC was met with the last patient completing the 1 year follow-up visit in ...

BOSTON - A new study finds that women who receive a false positive result on a screening mammogram are often lost to follow-up. If you have ever received a call about an abnormal mammogram, you know ...

Adequate outpatient follow-up within 30 days significantly reduces 30-day all-cause hospital readmissions, impacting hospital finances and patient care quality. The study analyzed 83 studies, ...

Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF. Visit NAP.edu/10766 to get more information about this ...

New study finds link between exercise variety and longer life - ...

We conducted 28 semistructured in-depth interviews with 12 women with an abnormal CBE at the primary health facility who did not have diagnostic follow-up, four community health workers, nine health ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...